SCHEMBL801511

SCHEMBL801511

Cc1ccccc1-c1nc(Nc2n[nH]c3ccc(F)cc23)c2sncc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 2/20 0.41
EGFR P00533 1/20 0.40
CYP1A2 P05177 8/20 0.40
CYP3A4 P08684 8/20 0.40
CYP2D6 P10635 6/20 0.40
HSD17B10 Q99714 5/20 0.40
CLK4 Q9HAZ1 5/20 0.40
ALOX15 P16050 4/20 0.40
CYP2C19 P33261 4/20 0.40
USP2 O75604 3/20 0.40
GSK3A P49840 2/20 0.39
GSK3B P49841 2/20 0.39
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37
GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12619094 0.87 USP1 (0.47) FADS1CYP1A2CYP3A4CYP2D6HSD17B10
SCHEMBL13938155 0.85 CYP1A2 (0.54) FADS1CYP1A2CYP3A4CYP2D6HSD17B10
SCHEMBL801504 0.77 AURKA (0.50) CYP1A2CYP3A4CYP2D6HSD17B10CLK4
SCHEMBL802053 0.75 GSK3A (0.46) FADS1EGFRCYP1A2CYP3A4CYP2D6
SCHEMBL801730 0.74 FADS1 (0.45) FADS1EGFRCYP1A2CYP3A4CYP2D6
SCHEMBL785479 0.74 CYP1A2 (0.61) CYP1A2CYP3A4CYP2D6HSD17B10CLK4
SCHEMBL801914 0.74 FADS1 (0.49) FADS1CYP1A2CYP3A4CYP2D6HSD17B10
SCHEMBL801639 0.74 GSK3A (0.50) FADS1EGFRCYP1A2CYP3A4CYP2D6
SCHEMBL802060 0.73 GSK3A (0.44) FADS1EGFRCYP1A2CYP3A4CYP2D6
SCHEMBL801894 0.73 EGFR (0.41) EGFRCYP1A2CYP3A4CYP2D6HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7390815-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 FADS1 3442/4885EGFR 154/4885CYP1A2 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.